Genmab acquieres worldwide rights for HUMAX-CD4
Genmab A/S announced that it has licensed from Medarex, Inc. the European and Asian rights to utilize Medarex's UltiMAb® technology to develop and commercialize antibodies raised against the CD4 antigen, including HuMax-CD4(TM), a fully human antibody that Genmab currently has in Phase III clinical studies to treat cutaneous T-cell lymphoma. With the acquisition of this new territory, Genmab now holds worldwide rights to HuMax®-CD4.
Under the terms of the agreement, Genmab has agreed to pay Medarex an upfront payment of USD 2 million, and Medarex is entitled to potential total milestone and license fee payments of USD 12.5 million, as well as royalties that could reach double digits for a successfully commercialized product in the new territories.
"We believe that consolidating the worldwide rights to HuMax-CD4 should help us leverage more value from our development work to date. We can build on that to move forward in Europe where we already have an orphan drug designation," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Almac Announces Expansion of Pharmaceutical Development Facilities
To-BBB obtains government loan of €1.2 million for clinical trial in brain cancer
Phylogica Peptide Fusion Kills Aggressive Breast Cancer Cells
VASTox identifiies novel compound that kill tubercolosis bacteria
